A new biotech funding program for startups working on new therapies, technologies and medical devices is offering up to $1 million in matching grants to help companies develop their ideas through to the proof of concept stage.
The Biomedical Translation Bridge program is an initiative of the Medical Research Future Fund. It’s run by MTPConnect – the Medical Technologies and Pharmaceuticals Industry Innovation Growth Centre – in partnership with several university programs, including BioCurate, UniQuest, the Medical Device Partnering Program, and the Bridge and BridgeTech programs, which are involved in the translation and commercialisation of health and medical research.
Since expressions of interest for BTB funding opened three weeks ago MTPConnect Managing Director and CEO, Dr Dan Grant, said more than 60 projects have already registered an interest.
“The BTB program provides a unique opportunity for life science innovators to secure significant financial support to take their research to the next stage along the translation and commercialisation pathway,” Dr Grant said.
“We’re looking to support projects that provide innovative solutions in any disease area using any therapeutic modality.
“The successful projects we back through the BTB program will lead to new therapies, technologies, medical devices and preventative interventions to improve the health of Australians.”